Ticovac Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The ticovac market size has grown strongly in recent years. It will grow from $4.31 million in 2025 to $4.63 million in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to endemic presence of tick-borne encephalitis, public health vaccination initiatives, growing outdoor activity exposure, hospital based immunization programs, regulatory approvals for tbe vaccines.

The ticovac market size is expected to see strong growth in the next few years. It will grow to $6.11 million in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to expansion of vaccination coverage in europe, rising travel to endemic regions, increasing climate driven tick populations, stronger preventive healthcare policies, investment in vaccine infrastructure. Major trends in the forecast period include rising demand for tick-borne disease vaccination, expansion of preventive travel immunization, growth of government led vaccination programs, increased awareness of vector-borne diseases, improved cold chain vaccine distribution.

The rising prevalence of tick-borne diseases is expected to drive the growth of the Ticovac market in the coming years. Tick-borne diseases are infections transmitted to humans through the bites of infected ticks, caused by bacteria, viruses, or parasites. Their increasing incidence is linked to factors such as climate change, expanding tick habitats, greater human exposure, and improved diagnostic methods. Ticovac plays a critical role in prevention by providing active immunization against tick-borne encephalitis (TBE), a potentially severe viral infection transmitted through tick bites. For example, in February 2024, the Centers for Disease Control and Prevention reported that the overall incidence of Lyme disease in the U.S. was 18.9 cases per 100,000 population, representing a 68.8% increase compared to previous years. Among high-incidence regions, the median rate rose 58% to 68.3 cases per 100,000, while for children aged 5-9 years, the incidence reached 16.5 cases per 100,000, reflecting an 11.5% increase. Consequently, the rising prevalence of tick-borne diseases is driving the Ticovac market.

The increasing focus on research and development (R&D) activities is also expected to support the growth of the Ticovac market. R&D involves systematic scientific investigation to create new products, improve existing ones, and develop innovative technologies. Rising R&D efforts are driven by growing demand for innovation, technological progress, and the need to address emerging global health challenges. These activities positively impact Ticovac by advancing vaccine formulations, enhancing efficacy, and ensuring its continued effectiveness against emerging strains of tick-borne encephalitis. For example, in February 2025, the National Center for Science and Engineering Statistics reported that U.S. research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, a rise of $48 billion. Therefore, the growing research and development efforts are driving the Ticovac market.

Key companies in the Ticovac market are focusing on innovative formulations, such as suspension liquid vaccines, to gain a competitive advantage. Suspension liquid vaccines are designed for intramuscular injection and are available in 0.5 mL doses suitable for both adults and pediatric patients. For instance, in September 2024, Pfizer Inc., a U.S.-based pharmaceutical company, launched Ticovac in Japan as the first vaccine aimed at preventing tick-borne encephalitis (TBE) in the region. The vaccine is offered in two versions - one for adults and one for children - both administered as 0.5 mL intramuscular injections, providing protection in areas where TBE is prevalent.

Major companies operating in the ticovac market are Pfizer Inc.

Europe was the largest region in the ticovac market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the ticovac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ticovac market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the ticovac market by increasing costs associated with imported vaccine ingredients, sterile packaging materials, and temperature controlled logistics systems. These tariff pressures have affected hospital pharmacies and government vaccination programs that rely on cross-border supply chains. Regions such as europe face moderate cost escalation due to dependence on imported vaccines. At the same time, tariffs are encouraging regional vaccine manufacturing investments. This is supporting long-term supply resilience and distribution stability.

The ticovac market research report is one of a series of new reports that provides ticovac market statistics, including ticovac industry global market size, regional shares, competitors with a ticovac market share, detailed ticovac market segments, market trends and opportunities, and any further data you may need to thrive in the ticovac industry. This ticovac market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

TicoVac is a vaccine designed to protect against tick-borne encephalitis (TBE), a viral infection primarily transmitted through tick bites or, less commonly, by consuming unpasteurized dairy products from infected animals. TBE affects the central nervous system and can result in serious neurological complications, including meningitis and encephalitis. TicoVac works by activating the immune system to recognize and combat the tick-borne encephalitis virus (TBEV) upon future exposure.

The main formulations of TicoVac are inactivated vaccines and live attenuated vaccines. Tick-borne encephalitis is a viral disease spread through infected tick bites, affecting the central nervous system and potentially causing severe neurological issues. The vaccine is used for tick-borne encephalitis, Japanese encephalitis, and rabies encephalitis, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The ticovac market consists of sales of pediatric vaccines, cardiovascular and metabolic products, anti-infective medications and rare disease medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.